Sugi Predict

Sugi Predict / Compounds / SCHEMBL400157

SCHEMBL400157

SCHEMBL400157

O=C1CC(C2=C3C=NC=C[N+]3(Cl)C(c3ccc4ccc(-c5ccccc5)nc4c3)=N2)C1

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ IGF1R P08069 6/20 0.32
▸ CYP3A4 P08684 2/20 0.31
▸ INSR P06213 2/20 0.31
▸ RIPK2 O43353 1/20 0.31
▸ ROCK2 O75116 1/20 0.31
▸ LATS1 O95835 1/20 0.31
▸ LCK P06239 1/20 0.31
▸ LYN P07948 1/20 0.31
▸ RET P07949 1/20 0.31
▸ ABCB1 P08183 1/20 0.31
▸ MET P08581 1/20 0.31
▸ FGFR1 P11362 1/20 0.31
▸ INSRR P14616 1/20 0.31
▸ FECH P22830 1/20 0.31
▸ MAPK3 P27361 1/20 0.31
▸ MARK3 P27448 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ FLT4 P35916 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL400252 0.91 IGF1R (0.31) IGF1RCYP3A4INSRRIPK2ROCK2
SCHEMBL400783 0.88 IGF1R (0.33) IGF1RCYP3A4INSRRIPK2ROCK2
SCHEMBL398430 0.87 IGF1R (0.33) NPC1RAB9AIGF1RCYP3A4INSR
SCHEMBL399578 0.86 IGF1R (0.32) IGF1RCYP3A4INSR
SCHEMBL401004 0.85 IGF1R (0.34) IGF1RCYP3A4INSRRIPK2ROCK2
SCHEMBL399358 0.85 IGF1R (0.44) IGF1RCYP3A4INSRRIPK2ROCK2
SCHEMBL397478 0.84 IGF1R (0.32) NPC1RAB9AIGF1RCYP3A4INSR
SCHEMBL400467 0.84 INSR (0.34) IGF1RINSRRIPK2ROCK2LATS1
SCHEMBL399390 0.84 IGF1R (0.32) IGF1RCYP3A4INSRRIPK2ROCK2
SCHEMBL3908924 0.83 NPC1 (0.33) NPC1RAB9AIGF1RCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168968-B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS LLC (US) 2017-08-23 — — EP disclosed
US-8735405-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-05-27 — — US disclosed
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 — — US disclosed
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2013-07-25 — — US disclosed
US-8367826-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-02-05 — — US disclosed
US-20120196847-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2012-08-02 — — US disclosed
US-20120077979-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2012-03-29 — — US disclosed
US-8101613-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-01-24 — — US disclosed
EP-2308879-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2011-04-13 — — EP disclosed
EP-2305682-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2011-04-06 — — EP disclosed
US-7820662-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-10-26 — — US disclosed
EP-2168968-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2010-03-31 — — EP disclosed
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-12-31 — — US disclosed
EP-1740591-B1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARM INC (US) 2009-06-17 — — EP disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077979-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 NPC1 3887/4885RAB9A 2985/4885IGF1R 1/4885
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 NPC1 3887/4885RAB9A 2985/4885IGF1R 1/4885
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 NPC1 3887/4885RAB9A 2985/4885IGF1R 1/4885
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 NPC1 3887/4885RAB9A 2985/4885IGF1R 1/4885
US-20120196847-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 NPC1 3887/4885RAB9A 2985/4885IGF1R 1/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 NPC1 3887/4885RAB9A 2985/4885IGF1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.